EGFR and non-small cell lung carcinoma: In combination with erlotinib, an EGFR tyrosine kinase inhibitor, fedratinib decreased STAT3 activation and increased apoptosis in erlotinib-resistant NSCLC cells, also inhibiting tumour growth in murine models [53].